
Genaco Biomedical Products Inc Profile last edited on: 4/8/2019
CAGE: 336E6
UEI:
Business Identifier: Molecular diagnostics Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
2707 Artie Street Building 100 Suite 20
Huntsville, AL 35805
Huntsville, AL 35805
(256) 425-0051 |
info@genaco.com |
www.genaco.com |
Location: Single
Congr. District: 05
County: Madison
Congr. District: 05
County: Madison
Public Profile
In October 2006, Genaco Biomedical Products Inc was acquired by the Dutch firm QIAGEN. Genaco Biomedical Products Inc products include commercial kits for prenatal screening and diagnosis of common genetic diseases. Genaco Biomedical Products, Inc (Genaco), is a post-genomic era biotechnology platform company, utilizing the information and technologies derived from the human genome project (HGP) for developing molecular differential diagnostics (MDD). The company's mission is to integrate high throughput technologies and develop molecular diagnostics that can guide the treatment of infectious diseases, cancer, and other diseases. Genaco currently provides diagnostics technologies for rapid and accurate identification of disease. Genaco is an innovator in the development of multiplex diagnostic assays through the incorporation of our proprietary technologies with the Luminex xMAP platform. Technologies Tem-PCR (Target-enriched multiplex PCR) and ROCASH (Reporter Oligo Capture after Specific Hybridization) are two unique technologies developed by Genaco scientists. Tem-PCR is a method for specific amplification of multiple nucleotide targets in a single assay system. ROCASH is a high-throughput method for specific detection of multiple single-base mutations. The firm uses Luminex's xMAP technology (Luminex Corporation, Austin, Texas) as our platform for the development of multiplex diagnostic assays. Instead of studying thousands of genes like other high throughput technologies, the xMAP studies only 100 at a time. While the xMAP's screening capability is not as vast, this array method is more reliable and because of the high reproducibility, it is the only FDA approved high throughput platform.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
5-9Revenue Range
.5M-1MVC funded?
YesPublic/Private
Privately HeldStock Info
----IP Holdings
1-4Awards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2006 | 2 | NIH | $333,711 | |
Project Title: Expression Profiling of microRNAs with Bead Array | ||||
2006 | 1 | Army | $69,957 | |
Project Title: Development of a High-Throughput Molecular Differentiation Device | ||||
2004 | 1 | NIH | $100,000 | |
Project Title: High Throughput Method for Cancer related HPV subtyping | ||||
2003 | 1 | NIH | $98,688 | |
Project Title: High Throughput Leukemia Diagnosis | ||||
1999 | 1 | NIH | $91,078 | |
Project Title: RT-PCR /Elisa Based Method for Leukemia Diagnosis |
Key People / Management
Dennis Grimaud -- CEO
Jian Han -- President
Chiungmei Lu
Jian Han -- President
Chiungmei Lu
Company News
There are no news available.